At the bedside: Innate immunity as an immunotherapy tool for hematological malignancies

Journal of Leukocyte Biology

Volumn 94, Issue 6, 2013, Pages 1141-1157

  Locatelli, Franco ^a,b   Merli, Pietro ^a   Rutella, Sergio ^a  

^a BAMBINO GESÙ CHILDREN S HOSPITAL   (Italy)

^b UNIVERSITY OF PAVIA   (Italy)

Author keywords

T cells; Graft versus host disease; Graft versus leukemia effect; Haploidentical hematopoietic stem cell transplantation; NK cells

Indexed keywords

BCG VACCINE; BISPHOSPHONIC ACID DERIVATIVE; BROMOHYDRIN PYROPHOSPHATE; CLOFARABINE; COMPACTIN; CYCLOPHOSPHAMIDE; DENILEUKIN DIFTITOX; EPRATUZUMAB; ETOPOSIDE; FLUDARABINE; GAMMA INTERFERON; HYDROCORTISONE; IMMUNOSTIMULATING AGENT; INTERLEUKIN 15; INTERLEUKIN 2; INTERLEUKIN 21; KRESTIN; METHYLPREDNISOLONE; MEVALONIC ACID; MONOCLONAL ANTIBODY; OKT 3; PAMIDRONIC ACID; PHOSPHOSTIM; RECOMBINANT GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; RECOMBINANT INTERLEUKIN 2; RITUXIMAB; T LYMPHOCYTE RECEPTOR ALPHA CHAIN; T LYMPHOCYTE RECEPTOR BETA CHAIN; THYMOCYTE ANTIBODY; UNCLASSIFIED DRUG; UNINDEXED DRUG; ZOLEDRONIC ACID;

ACUTE GRANULOCYTIC LEUKEMIA; ADJUVANT THERAPY; ADOPTIVE IMMUNOTHERAPY; ADOPTIVE TRANSFER; ADULT; ADVANCED CANCER; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ANTIGEN PRESENTING CELL; BASIC RESEARCH; BLADDER CANCER; CANCER IMMUNOTHERAPY; CANCER REGRESSION; CANCER RESEARCH; CHILD; CLINICAL PROTOCOL; CLINICAL RESEARCH; CYTOKINE PRODUCTION; CYTOTOXIC T LYMPHOCYTE; CYTOTOXICITY; DRUG DOSE INCREASE; GRAFT REJECTION; GRAFT VERSUS HOST REACTION; GRAFT VERSUS LEUKEMIA EFFECT; HEMATOLOGIC MALIGNANCY; HLA MATCHING; HODGKIN DISEASE; HUMAN; HUMAN CELL; IMMUNOTHERAPY; INNATE IMMUNITY; KIDNEY CARCINOMA; LEUKAPHERESIS; LEUKEMIA; LEUKEMIA CELL; LIVER CELL CARCINOMA; LOW DRUG DOSE; LUNG NON SMALL CELL CANCER; LYMPHOMA; LYMPHOPROLIFERATIVE DISEASE; MAJOR HISTOCOMPATIBILITY COMPLEX; MELANOMA; METABOLITE; MOLECULE; MYELOABLATIVE CONDITIONING; MYELODYSPLASTIC SYNDROME; NATURAL KILLER CELL; NEUROBLASTOMA; NONHUMAN; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROGNOSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; REVIEW; SOLID TUMOR; STEM CELL MOBILIZATION; T LYMPHOCYTE ACTIVATION; TRANSLATIONAL RESEARCH; TREATMENT RESPONSE; TUMOR CELL;

Γ-Δ T CELLS; GRAFT-VERSUS-HOST DISEASE; GRAFT-VERSUS-LEUKEMIA EFFECT; HAPLOIDENTICAL HEMATOPOIETIC STEM CELL TRANSPLANTATION; NK CELLS;

ADOPTIVE TRANSFER; ANTIGEN-PRESENTING CELLS; CLINICAL TRIALS, PHASE I AS TOPIC; CLINICAL TRIALS, PHASE II AS TOPIC; GRAFT VS HOST DISEASE; HEMATOLOGIC NEOPLASMS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; IMMUNITY, INNATE; KILLER CELLS, NATURAL; LYMPHOCYTE TRANSFUSION;

EID: 84888769265     PISSN: 07415400     EISSN: 19383673     Source Type: Journal    
DOI: 10.1189/jlb.0613343     Document Type: Review

References (145)

1. Copelan, E. A. (2006) Hematopoietic stem-cell transplantation. N. Eng. J. Med. 354, 1813-1826.
2. Appelbaum, F. R. (2001) Haematopoietic cell transplantation as immunotherapy. Nature 411, 385-389.
3. De Lalla, C, Rinaldi, A., Montagna, D., Azzimonti, L., Bernardo, M. E., Sangalli, L. M., Paganoni, A. M., Maccario, R., Di Cesare-Merlone, A., Zecca, M., Locatelli, F., Dellabona, P., Casorati, G. (2011) Invariant NKT cell reconstitution in pediatric leukemia patients given HLA-hap-loidentical stem cell transplantation defines distinct CD4+ and CD4 - subset dynamics and correlates with remission state. J. Immunol. 186, 4490-4499.
4. Barrett, A. J. (2008) Understanding and harnessing the graft-versus-leukaemia effect. Br. J. Haematol. 142, 877-888.
5. Spierings, E., Wieles, B., Goulmy, E. (2004) Minor histocompatibility antigens-big in tumour therapy. Trends Immunol. 25, 56-60.
6. Hambach, L., Goulmy, E. (2005) Immunotherapy of cancer through targeting of minor histocompatibility antigens. Curr. Opin. Immunol. 17, 202-210.
7. O'Reilly, R. J., Dao, T., Koehne, G, Scheinberg, D., Doubrovina, E. (2010) Adoptive transfer of unselected or leukemia-reactive T-cells in the treatment of relapse following allogeneic hematopoietic cell transplantation. Sem. Immunol. 22, 162-172.
8. Ferrara, J. L., Levine, J. E., Reddy, P., Holler, E. (2009) Graft-versus-host disease. Lancet 373, 1550-1561.
9. Zecca, M., Prete, A., Rondelli, R., Lanino, E., Balduzzi, A., Messina, C, Fagioli, F., Porta, F., Favre, C, Pession, A., Locatelli, F., AIEOP-BMT Group, Italian Association for Pediatric Hematology and Oncology-Bone Marrow Transplant (2002) Chronic graft-versus-host disease in children: incidence, risk factors, and impact on outcome. Blood 100, 1192-1200.
10. Rocha, V., Locatelli, F. (2008) Searching for alternative hematopoietic stem cell donors for pediatric patients. Bone Marrow Transplant. 41, 207-214.
11. Reisner, Y., Hagin, D., Martelli, M. F. (2011) Haploidentical hematopoietic transplantation: current status and future perspectives. Blood 118, 6006-6017.
12. Locatelli, F., Vinti, L., Palumbo, G, Rossi, F., Bertaina, A., Mastronuzzi, A., Bernardo, M. E., Rutella, S., Dellabona, P., Giorgiani, G, Moretta, A., Moretta, L. (2011) Strategies to optimize the outcome of children given T-cell depleted HLA-haploidentical hematopoietic stem cell transplantation. Best practice & research. Clin. Haematol. 24, 339-349.
13. Bachar-Lustig, E., Rachamim, N., Li, H. W., Lan, F., Reisner, Y. (1995) Megadose of T cell-depleted bone marrow overcomes MHC barriers in sublethally irradiated mice. Nat. Med. 1, 1268-1273.
14. Aversa, F., Tabilio, A., Terenzi, A., Velardi, A., Falzetti, F., Giannoni, C, Iacucci, R., Zei, T., Martelli, M. P., Gambelunghe, C, et al. (1994) Successful engraftment of T-cell-depleted haploidentical "three-loci" incompatible transplants in leukemia patients by addition of recombinant human granulocyte colony-stimulating factor-mobilized peripheral blood progenitor cells to bone marrow inoculum. Blood 84, 3948-3955.
15. Ruggeri, L., Capanni, M., Urbani, E., Perruccio, K, Shlomchik, W. D., Tosti, A., Posati, S., Rogaia, D., Frassoni, F., Aversa, F., Martelli, M. F., Velardi, A. (2002) Effectiveness of donor natural killer cell alloreactiv-ity in mismatched hematopoietic transplants. Science 295, 2097-2100.
16. Stern, M., Ruggeri, L., Mancusi, A., Bernardo, M. E., de Angelis, C., Bucher, C, Locatelli, F., Aversa, F., Velardi, A. (2008) Survival after T cell-depleted haploidentical stem cell transplantation is improved using the mother as donor. Blood 112, 2990-2995.
17. Klingebiel, T., Cornish, J., Labopin, M., Locatelli, F., Darbyshire, P., Handgretinger, R., Balduzzi, A., Owoc-Lempach, J., Fagioli, F., Or, R., Peters, C, Aversa, F., Polge, E., Dini, G, Rocha, V., Pediatric Diseases and Acute Leukemia Working Parties of the European Group for Blood and Marrow Transplantation (EBMT). (2010) Results and factors influencing outcome after fully haploidentical hematopoietic stem cell transplantation in children with very high-risk acute lymphoblastic leukemia: impact of center size: an analysis on behalf of the Acute Leukemia and Pediatric Disease Working Parties of the European Blood and Marrow Transplant group. Blood 115, 3437-3446.
18. Ciceri, F., Labopin, M., Aversa, F., Rowe, J. M., Bunjes, D., Lewalle, P., Nagler, A, Di Bartolomeo, P., Lacerda, J. F., Lupo Stanghellini, M. T., Polge, E., Frassoni, F., Martelli, M. F., Rocha, V., Acute Leukemia Working Party (ALWP) of European Blood and Marrow Transplant (EBMT) Group. (2008) A survey of fully haploidentical hematopoietic stem cell transplantation in adults with high-risk acute leukemia: a risk factor analysis of outcomes for patients in remission at transplantation. Blood 112, 3574-3581.
19. Aversa, F., Tabilio, A, Velardi, A, Cunningham, I., Terenzi, A, Fal-zetti, F., Ruggeri, L., Barbabietola, G., Aristei, C, Latini, P., Reisner, Y, Martelli, M. F. (1998) Treatment of high-risk acute leukemia with T-cell-depleted stem cells from related donors with one fully mismatched HLA haplotype. N. Eng. J. Med. 339, 1186-1193.
20. Aversa, F., Terenzi, A, Tabilio, A, Falzetti, F., Carotti, A, Ballanti, S., Felicini, R, Falcinelli, F., Velardi, A, Ruggeri, L., Aloisi, T., Saab, J. P., Santucci, A, Perruccio, K, Martelli, M. P., Mecucci, C, Reisner, Y, Martelli, M. F. (2005) Full haplotype-mismatched hematopoietic stem-cell transplantation: a phase II study in patients with acute leukemia at high risk of relapse. J. Clin. Oncol. 23, 3447-3454.
21. Leung, W., Iyengar, R, Turner, V., Lang, P., Bader, P., Conn, P., Niet-hammer, D., Handgretinger, R (2004) Determinants of antileukemia effects of allogeneic NK cells. J. Immunol. 172, 644-650.
22. Vivier, E., Raulet, D. H., Moretta, A, Caligiuri, M. A, Zitvogel, L., La-nier, L. L., Yokoyama, W. M., Ugolini, S. (2011) Innate or adaptive immunity? The example of natural killer cells. Science 331, 44-49.
23. Norell, H., Moretta, A, Silva-Santos, B., Moretta, L. (2013) At the bench: preclinical rationale for exploiting NK cells and 7Ô T lymphocytes for the treatment of high-risk leukemias. J. Leukoc. Biol. 94, 1123-1139.
24. Moretta, L., Biassoni, R, Bottino, C, Mingari, M. C, Moretta, A. (2000) Human NK-cell receptors. Immunol. Today 21, 420-422.
25. Colonna, M., Samaridis, J. (1995) Cloning of immunoglobulin-super-family members associated with HLA-C and HLA-B recognition by human natural killer cells. Science 268, 405-408.
26. Moretta, A., Bottino, C, Pende, D., Tripodi, G., Tambussi, G., Viale, O., Orengo, A, Barbaresi, M., Merli, A, Ciccone, E., et al. (1990) Identification of four subsets of human CD3-CD16+ natural killer (NK) cells by the expression of clonally distributed functional surface molecules: correlation between subset assignment of NK clones and ability to mediate specific alloantigen recognition. J. Exp. Med. 172, 1589-1598.
27. Moretta, A., Tambussi, G., Bottino, C, Tripodi, G., Merli, A, Ciccone, E., Pantaleo, G., Moretta, L. (1990) A novel surface antigen expressed by a subset of human CD3-CD16+ natural killer cells. Role in cell activation and regulation of cytolytic function. J. Exp. Med. 171, 695-714.
28. Moretta, A., Vitale, M., Bottino, C, Orengo, A. M., Morelli, L., Augugli-aro, R, Barbaresi, M., Ciccone, E., Moretta, L. (1993) P58 molecules as putative receptors for major histocompatibility complex (MHC) class I molecules in human natural killer (NK) cells. Anti-p58 antibodies reconstitute lysis of MHC class I-protected cells in NK clones displaying different specificities. J. Exp. Med. 178, 597-604.
29. Moretta, L., Locatelli, F., Pende, D., Marcenaro, E., Mingari, M. C, Moretta, A. (2011) Killer Ig-like receptor-mediated control of natural killer cell alloreactivity in haploidentical hematopoietic stem cell transplantation. Blood 117, 764-771.
30. Moretta, A., Bottino, C, Vitale, M., Pende, D., Biassoni, R., Mingari, M. C, Moretta, L. (1996) Receptors for HLA class-I molecules in human natural killer cells. Ann. Rev. Immunol. 14, 619-648.
31. Parham, P. (2005) MHC class I molecules and KIRs in human history, health and survival. Nat. Rev. Immunol. 5, 201-214.
32. Romagne, F., Andre, P., Spee, P., Zahn, S., Anfossi, N., Gauthier, L., Capanni, M., Ruggeri, L., Benson D. M., Jr., Blaser, B. W., Della Chiesa, M., Moretta, A, Vivier, E., Caligiuri, M. A, Velardi, A, Wagt-mann, N. (2009) Preclinical characterization of 1-7F9, a novel human anti-KIR receptor therapeutic antibody that augments natural killer-mediated killing of tumor cells. Blood 114, 2667-2677.
33. Thielens, A, Vivier, E., Romagne, F. (2012) NK cell MHC class I specific receptors (KIR): from biology to clinical intervention. Curr. Opin. Immunol. 24, 239-245.
34. Pende, D., Marcenaro, S., Falco, M., Martini, S., Bernardo, M. E., Mon-tagna, D., Romeo, E., Cognet, C, Martinetti, M., Maccario, R, Mingari, M. C, Vivier, E., Moretta, L., Locatelli, F., Moretta, A. (2009) Anti-leukemia activity of alloreactive NK cells in KIR ligand-mismatched haploidentical HSCT for pediatric patients: evaluation of the functional role of activating KIR and redefinition of inhibitory KIR specificity. Blood 113, 3119-3129.
35. Rutella, S., Rumi, C, Laurenti, L., Pierelli, L., Sora, F., Sica, S., Leone, G. (2000) Immune reconstitution after transplantation of autologous peripheral CD34+ cells: analysis of predictive factors and comparison with unselected progenitor transplants. Br. J. Haematol. 108, 105-115.
36. Curti, A, Ruggeri, L., D'Addio, A, Bontadini, A, Dan, E., Motta, M. R, Trabanelli, S., Giudice, V., Urbani, E., Martinelli, G., Paolini, S., Fruet, F., Isidori, A, Parisi, S., Bandini, G., Baccarani, M., Velardi, A, Lemoli, R. M. (2011) Successful transfer of alloreactive haploidentical KIR ligand-mismatched natural killer cells after infusion in elderly high risk acute myeloid leukemia patients. Blood 118, 3273-3279.
37. Chaleff, S., Otto, M., Barfield, R C, Leimig, T., Iyengar, R., Martin, J., Holiday, M., Houston, J., Geiger, T., Huppert, V., Handgretinger, R (2007) A large-scale method for the selective depletion of ex/3 T lymphocytes from PBSC for allogeneic transplantation. Cytotherapy 9, 746-754.
38. Locatelli, F., Pende, D., Mingari, M. C, Bertaina, A, Falco, M., Moretta, A., Moretta, L. (2013) Cellular and molecular basis of haploidentical hematopoietic stem cell transplantation in the successful treatment of high-risk leukemias: role of alloreactive NK cells. Front. Immunol. 4, 15.
39. Davies, S. M., Ruggieri, L., DeFor, T., Wagner, J. E., Weisdorf, D. J., Miller, J. S., Velardi, A, Blazar, B. R (2002) Evaluation of KIR ligand incompatibility in mismatched unrelated donor hematopoietic transplants. Killer immunoglobulin-like receptor. Blood 100, 3825-3827.
40. Farag, S. S., Bacigalupo, A, Eapen, M., Hurley, C, Dupont, B., Caligiuri, M A, Boudreau, C, Nelson, G., Oudshoorn, M., van Rood, J., Velardi, A, Maiers, M., Setterholm, M., Confer, D., Posch, P. E., Anasetti, C, Kamani, N., Miller, J. S., Weisdorf, D., Davies, S. M., KIR Study Group, Center for International Blood and Marrow Transplantation Research (2006) The effect of KIR ligand incompatibility on the outcome of unrelated donor transplantation: a report from the center for international blood and marrow transplant research, the European blood and marrow transplant registry, and the Dutch registry. Biol. Blood Marrow Transplant. 12, 876-884.
41. Bornhauser, M., Schwerdtfeger, R, Martin, H., Frank, K H., Theuser, C, Ehninger, G. (2004) Role of KIR ligand incompatibility in hematopoietic stem cell transplantation using unrelated donors. Blood 103, 2860-2861.
42. Giebel, S., Locatelli, F., Lamparelli, T., Velardi, A, Davies, S., Fru-mento, G., Maccario, R, Bonetti, F., Wojnar, J., Martinetti, M., Frassoni, F., Giorgiani, G., Bacigalupo, A, Holowiecki, J. (2003) Survival advantage with KIR ligand incompatibility in hematopoietic stem cell transplantation from unrelated donors. Blood 102, 814-819.
43. Willemze, R, Rodrigues, C. A, Labopin, M., Sanz, G., Michel, G., So-cie, G., Rio, B., Sirvent, A, Renaud, M., Madero, L., Mohty, M., Ferra, C, Garnier, F., Loiseau, P., Garcia, J., Lecchi, L., Kogler, G., Beguin, Y, Navarrete, C, Devos, T., Ionescu, I., Boudjedir, K, Herr, A. L., Gluckman, E., Rocha, V., Eurocord-Netcord and Acute Leukaemia Working Party of the EBMT (2009) KIR-ligand incompatibility in the graft-versus-host direction improves outcomes after umbilical cord blood transplantation for acute leukemia. Leukemia 23, 492-500.
44. Brunstein, C. G., Wagner, J. E., Weisdorf, D. J., Cooley, S., Noreen, H., Barker, J. N., DeFor, T., Verneris, M. R, Blazar, B. R, Miller, J. S. (2009) Negative effect of KIR alloreactivity in recipients of umbilical cord blood transplant depends on transplantation conditioning inten sity. Blood 113, 5628-5634.
45. Lowe, E. J., Turner, V, Handgretinger, R, Horwitz, E. M., Benaim, E., Hale, G. A, Woodard, P., Leung, W. (2003) T-cell alloreactivity dominates natural killer cell alloreactivity in minimally T-cell-depleted HLA-non-identical paediatric bone marrow transplantation. Br. J. Haematol. 123, 323-326.
46. Moretta, A., Bottino, C, Vitale, M., Pende, D., Cantoni, C, Mingari, M. C, Biassoni, R, Moretta, L. (2001) Activating receptors and core-ceptors involved in human natural killer cell-mediated cytolysis. Ann. Rev. Immunol. 19, 197-223.
47. Pende, D., Spaggiari, G. M., Marcenaro, S., Martini, S., Rivera, P., Ca-pobianco, A, Falco, M., Lanino, E., Pierri, I., Zambello, R, Bacigalupo, A, Mingari, M. C, Moretta, A, Moretta, L. (2005) Analysis of the receptor-ligand interactions in the natural killer-mediated lysis of freshly isolated myeloid or lymphoblastic leukemias: evidence for the involve ment of the poliovirus receptor (CD155) and nectin-2 (CD112). Blood 105, 2066-2073.
48. Biassoni, R, Cantoni, C, Falco, M., Verdiani, S., Bottino, C, Vitale, M., Conte, R, Poggi, A, Moretta, A, Moretta, L. (1996) The human leukocyte antigen (HLA)-C-specific "activatory" or "inhibitory" natural killer cell receptors display highly homologous extracellular domains but differ in their transmembrane and intracytoplasmic portions. J. Exp. Med. 183, 645-650.
49. Cognet, C, Farnarier, C, Gauthier, L., Frassati, C, Andre, P., Magerus-Chatinet, A, Anfossi, N., Rieux-Laucat, F., Vivier, E., Schleinitz, N. (2010) Expression of the HLA-C2-specific activating killer-cell Ig-like receptor KIR2DS1 on NK and T cells. Clin. Immunol. 135, 26-32.
50. Cooley, S., Trachtenberg, E., Bergemann, T. L., Saeteurn, K, Klein, J., Le, C. T., Marsh, S. G., Guethlein, L. A, Parham, P., Miller, J. S., Weisdorf, D. J. (2009) Donors with group B KIR haplotypes improve relapse-free survival after unrelated hematopoietic cell transplantation for acute myelogenous leukemia. Blood 113, 726-732.
51. Stringaris, K, Adams, S., Uribe, M., Eniafe, R, Wu, C. O., Savani, B. N., Barrett, A. J. (2010) Donor KIR Genes 2DL5A, 2DS1 and 3DS1are associated with a reduced rate of leukemia relapse after HLA-iden-tical sibling stem cell transplantation for acute myeloid leukemia but not other hematologic malignancies. Biol. Blood Marrow Transplant. 16, 1257-1264.
52. Cooley, S., Weisdorf, D. J., Guethlein, L. A., Klein, J. P., Wang, T., Le, C. T., Marsh, S. G., Geraghty, D., Spellman, S., Haagenson, M. D., Lad-ner, M., Trachtenberg, E., Parham, P., Miller, J. S. (2010) Donor selection for natural killer cell receptor genes leads to superior survival after unrelated transplantation for acute myelogenous leukemia. Blood 116, 2411-2419.
53. Venstrom, J. M., Pittari, G., Gooley, T. A., Chewning, J. H., Spellman, S., Haagenson, M., Gallagher, M. M., Malkki, M., Petersdorf, E., Dupont, B., Hsu, K. C. (2012) HLA-C-dependent prevention of leukemia relapse by donor activating KIR2DS1. N. Eng. J. Med. 367, 805-816.
54. Fauriat, C, Ivarsson, M. A, Ljunggren, H. G., Malmberg, K. J., Mi-chaelsson, J. (2010) Education of human natural killer cells by activating killer cell immunoglobulin-like receptors. Blood 115, 1166-1174.
55. Sivori, S., Carlomagno, S., Falco, M., Romeo, E., Moretta, L., Moretta, A. (2011) Natural killer cells expressing the KIR2DS1-activating receptor efficiently kill T-cell blasts and dendritic cells: implications in hap-loidentical HSCT. Blood 117, 4284-4292.
56. Moretta, A., Pende, D., Locatelli, F., Moretta, L. (2009) Activating and inhibitory killer immunoglobulin-like receptors (KIR) in haploidentical haemopoietic stem cell transplantation to cure high-risk leukaemias. Clin. Exp. Immunol. 157, 325-331.
57. + NK cells in haploidentical hematopoietic stem cell transplantation. J. Leukoc. Biol. 90, 661-667.
58. Marcenaro, E., Pesce, S., Sivori, S., Carlomagno, S., Moretta, L., Moretta, A. (2013) KIR2DS1-dependent acquisition of CCR7 and migratory properties by human NK cells interacting with allogeneic HLA-C2+ DCs or T-cell blasts. Blood 121, 3396-3401.
59. Hsu, K. C, Keever-Taylor, C. A, Wilton, A, Pinto, C, Heller, G., Arkun, K, O'Reilly, R J., Horowitz, M. M., Dupont, B. (2005) Improved outcome in HLA-identical sibling hematopoietic stem-cell transplantation for acute myelogenous leukemia predicted by KIR and HLA genotypes. Blood 105, 4878-4884.
60. Eisenbeis, C. F., Grainger, A, Fischer, B., Baiocchi, R. A, Carrodeguas, L., Roychowdhury, S., Chen, L., Banks, A. L., Davis, T., Young, D., Kel-bick, N., Stephens, J., Byrd, J. C, Grever, M. R, Caligiuri, M. A, Porcu, P. (2004) Combination immunotherapy of B-cell non-Hodgkin's lym-phoma with rituximab and interleukin-2: a preclinical and phase I study. Clin. Cancer Res. 10, 6101-6110.
61. Gluck, W. L., Hurst, D., Yuen, A, Levine, A. M., Dayton, M. A, Gocker-man, J. P., Lucas, J., Denis-Mize, K, Tong, B., Navis, D., Difrancesco, A, Milan, S., Wilson, S. E., Wolin, M. (2004) Phase I studies of inter-leukin (IL)-2 and rituximab in B-cell non-hodgkin's lymphoma: IL-2 mediated natural killer cell expansion correlations with clinical response. Clin. Cancer Res. 10, 2253-2264.
62. Bowles, J. A, Wang, S. Y, Link, B. K, Allan, B., Beuerlein, G., Campbell, M. A, Marquis, D., Ondek, B., Wooldridge, J. E., Smith, B. J., Bre-itmeyer, J. B., Weiner, G. J. (2006) Anti-CD20 monoclonal antibody with enhanced affinity for CD16 activates NK cells at lower concentrations and more effectively than rituximab. Blood 108, 2648-2654.
63. Miller, J. S., Soignier, Y, Panoskaltsis-Mortari, A, McNearney, S. A, Yun, G. H., Fautsch, S. K, McKenna, D., Le, C, Defor, T. E., Burns, L. J., Orchard, P. J., Blazar, B. R, Wagner, J. E., Slungaard, A, Weisdorf, D. J., Okazaki, I. J., McGlave, P. B. (2005) Successful adoptive transfer and in vivo expansion of human haploidentical NK cells in patients with cancer. Blood 105, 3051-3057.
64. Rubnitz, J. E., Inaba, H., Ribeiro, R. C, Pounds, S., Rooney, B., Bell, T., Pui, C. H., Leung, W. (2010) NKAML: a pilot study to determine the safety and feasibility of haploidentical natural killer cell transplantation in childhood acute myeloid leukemia. J. Clin. Oncol. 28, 955-959.
65. + progenitor cells and subsequent infusion after HLA-mis-matched allogeneic hematopoietic cell transplantation: a feasibility study. Bone Marrow Transplant. 45, 1038-1046.
66. Stern, M., Passweg, J. R, Meyer-Monard, S., Esser, R, Tonn, T., So-erensen, J., Paulussen, M., Gratwohl, A, Klingebiel, T., Bader, P., Tichelli, A, Schwabe, D., Koehl, U. (2013) Pre-emptive immunotherapy with purified natural killer cells after haploidentical SCT: a prospective phase II study in two centers. Bone Marrow Transplant. 48, 433-438.
67. Bonneville, M., O'Brien, R L., Born, W. K. (2010) 7Ô T cell effector functions: a blend of innate programming and acquired plasticity. Nat. Rev. Immunol. 10, 467-478.
68. Andreu-Ballester, J. C, Tormo-Calandin, C, Garcia-Ballesteros, C, Per-ez-Griera, J., Amigo, V., Almela-Quilis, A, Ruiz Del Castillo, J., Penar-roja-Otero, C, Ballester, F. (2013) Association of y8 T cells with disease severity and mortality in septic patients. Clin. Vaccine Immunol. 20, 738-746.
69. Spencer, C. T., Abate, G., Sakala, I. G., Xia, M., Truscott, S. M., Eickhoff, C. S., Linn, R, Blazevic, A, Metkar, S. S., Peng, G., Froelich, C. J., Hoft, D. F. (2013) Granzyme A produced by 79Ô2 T cells induces human macrophages to inhibit growth of an intracellular pathogen. PLoS Pathog. 9, e1003119.
70. Sutton, C. E., Mielke, L. A, Mills, K. H. (2012) IL-17-producing y8 T cells and innate lymphoid cells. Eur. J. Immunol. 42, 2221-2231.
71. Girardi, M., Oppenheim, D. E., Steele, C. R, Lewis, J. M., Glusac, E., Filler, R, Hobby, P., Sutton, B., Tigelaar, R E., Hayday, A. C. (2001) Regulation of cutaneous malignancy by yS T cells. Science 294, 605-609.
72. Hayday, A. C. (2009) yS T cells and the lymphoid stress-surveillance response. Immunity 31, 184-196.
73. Willcox, C. R, Pitard, V., Netzer, S., Couzi, L., Salim, M., Silberzahn, T., Moreau, J. F., Hayday, A. C, Willcox, B. E., Dechanet-Merville, J. (2012) Cytomegalovirus and tumor stress surveillance by binding of a human 7Ô T cell antigen receptor to endothelial protein C receptor. Nat. Immunol. 13, 872-879.
74. Strid, J., Sobolev, O., Zafirova, B., Polic, B., Hayday, A. (2011) The in-traepithelial T cell response to NKG2D-ligands links lymphoid stress surveillance to atopy. Science 334, 1293-1297.
75. Jameson, J., Havran, W. L. (2007) Skin 7Ô T-cell functions in homeo-stasis and wound healing. Immunol. Rev. 215, 114-122.
76. Braza, M. S., Klein, B., Fiol, G., Rossi, J. F. (2011) yS T-cell killing of primary follicular lymphoma cells is dramatically potentiated by GA101, a type II glycoengineered anti-CD20 monoclonal antibody. Haemato-logica 96, 400-407.
77. Burjanadze, M., Condomines, M., Reme, T., Quittet, P., Latry, P., Lu-gagne, C, Romagne, F., Morel, Y, Rossi, J. F., Klein, B., Lu, Z. Y (2007) In vitro expansion of y8 T cells with anti-myeloma cell activity by phosphostim and IL-2 in patients with multiple myeloma. Br. J. Haematol. 139, 206-216.
78. Saitoh, A, Narita, M., Watanabe, N., Tochiki, N., Satoh, N., Takizawa, J., Furukawa, T., Toba, K, Aizawa, Y, Shinada, S., Takahashi, M. (2008) Anti-tumor cytotoxicity of 7Ô T cells expanded from peripheral blood cells of patients with myeloma and lymphoma. Med. Oncol. 25, 137-147.
79. Kunzmann, V., Bauer, E., Feurle, J., Weissinger, F., Tony, H. P., Wil-helm, M. (2000) Stimulation of 7Ô T cells by aminobisphosphonates and induction of antiplasma cell activity in multiple myeloma. Blood 96, 384-392.
80. D'Asaro, M., La Mendola, C, Di Liberto, D., Orlando, V., Todaro, M., Spina, M., Guggino, G., Meraviglia, S., Caccamo, N., Messina, A, Salerno, A, Di Raimondo, F., Vigneri, P., Stassi, G., Fournie, J. J., Dieli, F. (2010) V79VÔ2 T lymphocytes efficiently recognize and kill zoledro-nate-sensitized, imatinib-sensitive, and imatinib-resistant chronic myelogenous leukemia cells. J. Immunol. 184, 3260-3268.
81. Corvaisier, M., Moreau-Aubry, A, Diez, E., Bennouna, J., Mosnier, J. F., Scotet, E., Bonneville, M., Jotereau, F. (2005) V - 9VÔ2 T cell response to colon carcinoma cells. J. Immunol. 175, 5481-5488.
82. Kobayashi, H., Tanaka, Y, Yagi, J., Osaka, Y, Nakazawa, H., Uchiyama, T., Minato, N., Toma, H. (2007) Safety profile and anti-tumor effects of adoptive immunotherapy using 7Ô T cells against advanced renal cell carcinoma: a pilot study. Cancer Immunol. Immunother. 56, 469-476.
83. Viey, E., Fromont, G., Escudier, B., Morel, Y, Da Rocha, S., Chouaib, S., Caignard, A. (2005) Phosphostim-activated 7Ô T cells kill autologous metastatic renal cell carcinoma. J. Immunol. 174, 1338-1347.
84. Viey, E., Lucas, C, Romagne, F., Escudier, B., Chouaib, S., Caignard, A. (2008) Chemokine receptors expression and migration potential of tumor-infiltrating and peripheral-expanded V79VÔ2 T cells from renal cell carcinoma patients. J. Immunother. 31, 313-323.
85. Argentati, K, Re, F., Serresi, S., Tucci, M. G., Bartozzi, B., Bernardini, G., Provinciali, M. (2003) Reduced number and impaired function of circulating 7Ô T cells in patients with cutaneous primary melanoma. J. Invest. Dermatol. 120, 829-834.
86. Zheng, B. J., Ng, S. P., Chua, D. T., Sham, J. S., Kwong, D. L., Lam, C. K, Ng, M. H. (2002) Peripheral 7Ô T-cell deficit in nasopharyngeal carcinoma. Int. J. Cancer. 99, 213-217.
87. Gertner-Dardenne, J., Castellano, R, Mamessier, E., Garbit, S., Koch-bati, E., Etienne, A, Charbonnier, A, Collette, Y, Vey, N., Olive, D. (2012) Human VÔ9VÔ2 T cells specifically recognize and kill acute myeloid leukemic blasts. J. Immunol. 188, 4701-4708.
88. Godder, K. T., Henslee-Downey, P. J., Mehta, J., Park, B. S., Chiang, K Y, Abhyankar, S., Lamb, L. S. (2007) Long term disease-free survival in acute leukemia patients recovering with increased 7Ô T cells after partially mismatched related donor bone marrow transplantation. Bone Marrow Transplant. 39, 751-757.
89. Drobyski, W. R., Majewski, D., Hanson, G. (1999) Graft-facilitating doses of ex vivo activated 7Ô T cells do not cause lethal murine graft-vs.-host disease. Biol. Blood Marrow Transplant. 5, 222-230.
90. Bertaina, A, Romano, M., Rutella, S., Palumbo, G., Pagliara, D., Cecca-relli, S., Brescia, L. P., Pira, G. L., Cocca, F., Bernardo, M. E., Milano, G. M., Pende, D., Falco, M., Moretta, L., Locatelli, F. (2012) HLA haploidentical stem cell transplantation after removal of ex/3+ T lymphocytes and B lymphocytes is an effective treatment for children with life-threatening, non-malignant disorders. ASH Annual Meeting Abstracts 120, 2018.
91. Li Pira, G., Landi, F., Filippini, P., Giustiniani, P., Bertaina, A., Pagli-ara, D., Pinto, R. M., Girardi, K, Del Principe, G., Ceccarelli, S., Loca-telli, F., Rutella, S. (2012) Negative depletion of B cells and T cells expressing the a/3 chain of the T-cell receptor (TCR) for haploidentical stem cell transplantation. ASH Annual Meeting Abstracts 120, 343.
92. Burk, M. R, Mori, L., De Libero, G. (1995) Human V79VÔ2 cells are stimulated in a cross-reactive fashion by a variety of phosphorylated metabolites. Eur. J. Immunol. 25, 2052-2058.
93. Tanaka, Y., Morita, C. T., Nieves, E., Brenner, M. B., Bloom, B. R (1995) Natural and synthetic non-peptide antigens recognized by human 7Ô T cells. Nature 375, 155-158.
94. Harly, C, Guillaume, Y., Nedellec, S., Peigne, C. M., Monkkonen, H., Monkkonen, J., Li, J., Kuball, J., Adams, E. J., Netzer, S., Dechanet-Mer-ville, J., Léger, A, Herrmann, T., Breathnach, R, Olive, D., Bonneville, M., Scotet, E. (2012) Key implication of CD277/butyrophilin-3 (BTN3A) in cellular stress sensing by a major human 7Ô T-cell subset. Blood 120, 2269-2279.
95. Belmant, C, Espinosa, E., Poupot, R, Peyrat, M. A, Guiraud, M., Po-quet, Y, Bonneville, M., Fournie, J. J. (1999) 3-Formyl-l-butyl pyrophosphate A novel mycobacterial metabolite-activating human 7Ô T cells. J. Biol. Chem. 274, 32079-32084.
96. Feurle, J., Espinosa, E., Eckstein, S., Pont, F., Kunzmann, V., Fournie, J. J., Herderich, M., Wilhelm, M. (2002) Escherichia coli produces phos-phoantigens activating human 7Ô T cells. J. Biol. Chem. 277, 148-154.
97. Gober, H. J., Kistowska, M., Angman, L., Jeno, P., Mori, L., De Libero, G. (2003) Human T cell receptor 7Ô cells recognize endogenous me-valonate metabolites in tumor cells. J. Exp. Med. 197, 163-168.
98. Li, J., Herold, M. J., Kimmel, B., Muller, L, Rincon-Orozco, B., Kunzmann, V-, Herrmann, T. (2009) Reduced expression of the meval-onate pathway enzyme farnesyl pyrophosphate synthase unveils recognition of tumor cells by V79VÔ2 T cells. J. Immunol. 182, 8118-8124.
99. Roelofs, A. J., Jauhiainen, M., Monkkonen, H., Rogers, M. J., Monkkonen, J., Thompson, K (2009) Peripheral blood monocytes are responsible for 7Ô T cell activation induced by zoledronic acid through accumulation of IPP/DMAPP. Br. J. Haematol. 144, 245-250.
100. Simoni, D., Gebbia, N., Invidiata, F. P., Eleopra, M., Marchetti, P., Ron-danin, R, Baruchello, R, Provera, S., Marchioro, C, Tolomeo, M., Marinelli, L., Limongelli, V., Novellino, E., Kwaasi, A, Dunford, J., Buccheri, S., Caccamo, N., Dieli, F. (2008) Design, synthesis, and biological evaluation of novel aminobisphosphonates possessing an in vivo antitumor activity through a 75-T lymphocytes-mediated activation mechanism. J. Med. Chem. 51, 6800-6807.
101. Thompson, K, Rojas-Navea, J., Rogers, M. J. (2006) Alkylamines cause V79VÔ2 T-cell activation and proliferation by inhibiting the mevalonate pathway. Blood 107, 651-654.
102. Cairo, C, Sagnia, B., Cappelli, G., Colizzi, V., Leke, R G., Leke, R. J., Pauza, C. D. (2013) Human cord blood 7Ô T cells expressing public V72 chains dominate the response to bisphosphonate plus interleukin-15. Immunology 138, 346-360.
103. Ness-Schwickerath, K J., Jin, C, Morita, C. T. (2010) Cytokine requirements for the differentiation and expansion of IL-17A-and IL-22-pro-ducing human V72VÔ2 T cells. J. Immunol. 184, 7268-7280.
104. Inatsuka, C, Yang, Y, Gad, E., Rastetter, L., Disis, M. L., Lu, H. (2013) y 8 T cells are activated by polysaccharide K (PSK) and contribute to the anti-tumor effect of PSK. Cancer Immunol. Immunother. 62, 1335-1345.
105. Takeuchi, A, Dejima, T., Yamada, H., Shibata, K, Nakamura, R, Eto, M., Nakatani, T., Naito, S., Yoshikai, Y (2011) IL-17 production by y8 T cells is important for the antitumor effect of Mycobacterium bovis bacillus Calmette-Guerin treatment against bladder cancer. Eur. J. Immunol. 41, 246-251.
106. DeBarros, A, Chaves-Ferreira, M., d'Orey, F., Ribot, J. C, Silva-Santos, B. (2011) CD70-CD27 interactions provide survival and proliferative signals that regulate T cell receptor-driven activation of human 7Ô peripheral blood lymphocytes. Eur. J. Immunol. 41, 195-201.
107. Cabillic, F., Toutirais, O., Lavoue, V., de La Pintiere, C. T., Daniel, P., Rioux-Leclerc, N., Turlin, B., Monkkonen, H., Monkkonen, J., Boud-jema, K, Catros, V., Bouet-Toussaint, F. (2010) Aminobisphosphonate-pretreated dendritic cells trigger successful V79VÔ2 T cell amplification for immunotherapy in advanced cancer patients. Cancer Immunol. Immunother. 59, 1611-1619.
108. Otto, M., Barfield, R C, Iyengar, R., Gatewood, J., Muller, I., Holladay, M. S., Houston, J., Leung, W., Handgretinger, R (2005) Human 7Ô T cells from G-CSF-mobilized donors retain strong tumoricidal activity and produce immunomodulatory cytokines after clinical-scale isolation. J. Immunother. 28, 73-78.
109. Otto, M., Barfield, R C, Martin, W. J., Iyengar, R, Leung, W., Leimig, T., Chaleff, S., Gillies, S. D., Handgretinger, R (2005) Combination immunotherapy with clinical-scale enriched human 7Ô T cells, hul4.18 antibody, and the immunocytokine Fc-IL7 in disseminated neuroblas-toma. Clin. Cancer Res. 11,8486-8491.
110. Siegers, G. M., Dhamko, H., Wang, X. H., Mathieson, A. M., Kosaka, Y, Felizardo, T. C, Medin, J. A, Tohda, S., Schueler, J., Fisch, P., Keating, A. (2011) Human VÔ1 7Ô T cells expanded from peripheral blood exhibit specific cytotoxicity against B-cell chronic lymphocytic leukemia-derived cells. Cytotherapy 13, 753-764.
111. Siegers, G. M., Felizardo, T. C, Mathieson, A. M., Kosaka, Y, Wang, X. H., Medin, J. A, Keating, A. (2011) Anti-leukemia activity of in vitro-expanded human 7Ô T cells in a xenogeneic Ph+ leukemia model. PLoS One6, el6700.
112. Ma, Y, Aymeric, L., Locher, C, Mattarollo, S. R., Delahaye, N. F., Pereira, P., Boucontet, L., Apetoh, L., Ghiringhelli, F., Casares, N., La-sarte, J. J., Matsuzaki, G., Ikuta, K, Ryffel, B., Benlagha, K, Tesniere, A, Ibrahim, N., Dechanet-Merville, J., Chaput, N., Smyth, M. J., Kro-emer, G., Zitvogel, L. (2011) Contribution of ILrl7-producing 7 8 T cells to the efficacy of anticancer chemotherapy.J. Exp. Med. 208, 491-503.
113. Gertner-Dardenne, J., Bonnafous, C, Bezombes, C, Capietto, A. H., Scaglione, V., Ingoure, S., Cendron, D., Gross, E., Lepage, J. F., Quillet-Mary, A, Ysebaert, L., Laurent, G., Sicard, H., Fournie, J. J. (2009) Bromohydrin pyrophosphate enhances antibody-dependent cell-mediated cytotoxicity induced by therapeutic antibodies. Blood 113, 4875-4884.
114. Tokuyama, H., Hagi, T., Mattarollo, S. R, Morley, J., Wang, Q., So, H. F., Moriyasu, F., Nieda, M., Nicol, A. J. (2008) V79VÔ2 T cell cytotoxicity against tumor cells is enhanced by monoclonal antibody drug-s-rituximab and trastuzumab. Int. J. Cancer122, 2526-2534.
115. Wilhelm, M., Kunzmann, V., Eckstein, S., Reimer, P., Weissinger, F., Ruediger, T., Tony, H. P. (2003) 7Ô T cells for immune therapy of patients with lymphoid malignancies. Blood 102, 200-206.
116. Dieli, F., Vermijlen, D., Fulfaro, F., Caccamo, N., Meraviglia, S., Cicero, G, Roberts, A., Buccheri, S., D'Asaro, M., Gebbia, N., Salerno, A, Eberl, M., Hayday, A. C. (2007) Targeting human 7Ô T cells with zole-dronate and interleukin-2 for immunotherapy of hormone-refractory prostate. Cancer Res. 67, 7450-7457.
117. Meraviglia, S., Eberl, M., Vermijlen, D., Todaro, M., Buccheri, S., Cicero, G., La Mendola, C, Guggino, G., D'Asaro, M., Orlando, V., Scarpa, F., Roberts, A, Caccamo, N., Stassi, G., Dieli, F., Hayday, A. C. (2010) In vivo manipulation of V79VÔ2 T cells with zoledronate and low-dose interleukin-2 for immunotherapy of advanced breast cancer patients. Clin. Exp. Immunol. 161, 290-297.
118. Kobayashi, H., Tanaka, Y, Yagi, J., Minato, N., Tanabe, K (2011) Phase I/II study of adoptive transfer of 7Ô T cells in combination with zoledronic acid and IL-2 to patients with advanced renal cell carcinoma. Cancer Immunol. Immunother. 60, 1075-1084.
119. Abe, Y, Muto, M., Nieda, M., Nakagawa, Y, Nicol, A, Kaneko, T., Goto, S., Yokokawa, K, Suzuki, K (2009) Clinical and immunological evaluation of zoledronate-activated V79 7Ô T-cell-based immunotherapy for patients with multiple myeloma. Exp. Hematol. 37, 956-968.
120. Bennouna, J., Bompas, E., Neidhardt, E. M., Rolland, F., Philip, I., Ga-lea, C, Salot, S., Saiagh, S., Audrain, M., Rimbert, M., Lafaye-de Mi-cheaux, S., Tiollier, J., Négrier, S. (2008) Phase-I study of Innacell gammadelta, an autologous cell-therapy product highly enriched in gamma9delta2 T lymphocytes, in combination with IL-2, in patients with metastatic renal cell carcinoma. Cancer Immunol Immunother. 57, 1599-1609.
121. Sakamoto, M., Nakajima, J., Murakawa, T., Fukami, T., Yoshida, Y, Mu-rayama, T., Takamoto, S., Matsushita, H., Kakimi, K (2011) Adoptive immunotherapy for advanced non-small cell lung cancer using zoledro-nate-expanded 7Ô T cells: A phase I clinical study. J. Immunother. 34, 202-211.
122. Noguchi, A, Kaneko, T., Kamigaki, T., Fujimoto, K, Ozawa, M., Saito, M., Ariyoshi, N., Goto, S. (2011) Zoledronate-activated V79 7Ô T cell-based immunotherapy is feasible and restores the impairment of 7Ô T cells in patients with solid tumors. Cytotherapy. 13, 92-97.
123. Kondo, M., Sakuta, K, Noguchi, A, Ariyoshi, N., Sato, K, Sato, S., Ho-soi, A, Nakajima, J., Yoshida, Y, Shiraishi, K, Nakagawa, K, Kakimi, K (2008) Zoledronate facilitates large-scale ex vivo expansion of functional 7Ô T cells from cancer patients for use in adoptive immunotherapy. Cytotherapy. 10, 842-856.
124. Salot, S., Laplace, C, Saiagh, S., Bercegeay, S., Tenaud, I., Cassidanius, A, Romagne, F., Dreno, B., Tiollier, J. (2007) Large scale expansion of y9Ô2 T lymphocytes: Innacell 7Ô cell therapy product. J. Immunol. Methods. 326, 63-75.
125. Brandes, M., Willimann, K, Moser, B. (2005) Professional antigen-presentation function by human 7Ô T Cells. Science. 309, 264-268.
126. + a/3 T cell responses. Proc. Natl. Acad. Sci. U. S. A. 106, 2307-2312.
127. Devilder, M. C, Maillet, S., Bouyge-Moreau, L, Donnadieu, E., Bonneville, M., Scotet, E. (2006) Potentiation of antigen-stimulated V79VÔ2 T cell cytokine production by immature dendritic cells (DC) and reciprocal effect on DC maturation. J. Immunol. 176, 1386-1393.
128. Cendron, D., Ingoure, S., Martino, A, Casetti, R, Horand, F., Romagne, F., Sicard, H., Fournie, J. J., Poccia, F. (2007) A tuberculosis vaccine based on phosphoantigens and fusion proteins induces distinct y8 and a/3 T cell responses in primates. Eur. J. Immunol. 37, 549-565.
129. Kong, Y., Cao, W., Xi, X., Ma, C, Cui, L., He, W. (2009) The NKG2D ligand ULBP4 binds to TCR79/Ô2 and induces cytotoxicity to tumor cells through both TCR7Ô and NKG2D. Blood. 114, 310-317.
130. Gomes, A. Q., Correia, D. V., Grosso, A. R., Lanca, T., Ferreira, C, Lacerda, J. F., Barata, J. T., Silva, M. G., Silva-Santos, B. (2010) Identification of a panel of ten cell surface protein antigens associated with immunotargeting of leukemias and lymphomas by peripheral blood y8 T cells. Haematologica. 95, 1397-1404.
131. Shojaei, H., Oberg, H. H., Juricke, M., Marischen, L., Kunz, M., Mund-henke, C, Gieseler, F., Kabelitz, D., Wesch, D. (2009) Toll-like receptors 3 and 7 agonists enhance tumor cell lysis by human 7Ô T cells. Cancer Res. 69, 8710-8717.
132. Toutirais, O., Cabillic, F., Le Friec, G., Salot, S., Loyer, P., Le Gallo, M., Desille, M., de La Pintiere, C. T., Daniel, P., Bouet, F., Catros, V. (2009) DNAX accessory molecule-1 (CD226) promotes human hepato-cellular carcinoma cell lysis by V79VÔ2 T cells. Eur. J. Immunol. 39, 1361-1368.
133. Lanca, T., Correia, D. V., Moita, C. F., Raquel, H., Neves-Costa, A, Ferreira, C, Ramalho, J. S., Barata, J. T., Moita, L. F., Gomes, A. Q., Silva-Santos, B. (2010) The MHC class Ib protein ULBP1 is a nonredundant determinant of leukemia/lymphoma susceptibility to 7Ô T-cell cytotoxicity. Blood. 115, 2407-2411.
134. Izumi, T., Kondo, M., Takahashi, T., Fujieda, N., Kondo, A, Tamura, N., Murakawa, T., Nakajima, J., Matsushita, H., Kakimi, K (2013) Ex vivo characterization of 7Ô T-cell repertoire in patients after adoptive transfer of V79VÔ2 T cells expressing the interleukin-2 receptor /3-chain and the common. chain. Cytotherapy. 15, 481-491.
135. Cooley, S., Verneris, M. R, Curtsinger, J., McKenna, D., Weisdorf, D. J., Blazar, B. R., Waldmann, T. A, Miller, J. S. (2012) Recombinant human IL-15 promotes in vivo expansion of adoptively transferred NK cells in a first-in-human phase I dose escalation study in patients with AML. Blood. 120, 894.
136. Correia, D. V., Fogli, M., Hudspeth, K, da Silva, M. G., Mavilio, D., Silva-Santos, B. (2011) Differentiation of human peripheral blood VÔ1+ T cells expressing the natural cytotoxicity receptor NKp30 for recognition of lymphoid leukemia cells. Blood 118, 992-1001.
137. Ni, J., Miller, M., Stojanovic, A, Garbi, N., Cerwenka, A. (2012) Sustained effector function of IL-12/15/18-preactivated NK cells against established tumors. J. Exp. Med. 209, 2351-2365.
138. Romee, R, Schneider, S. E., Leong, J. W., Chase, J. M., Keppel, C. R, Sullivan, R. P., Cooper, M. A, Fehniger, T. A. (2012) Cytokine activation induces human memory-like NK cells. Blood. 120, 4751-4760.
139. Pizzitola, I., Agostoni, V., Cribioli, E., Pule, M., Rousseau, R., Finney, H., Lawson, A., Biondi, A., Biagi, E., Marin, V. (2011) In vitro comparison of three different chimeric receptor-modified effector T-cell populations for leukemia cell therapy. J. Immunother. 34, 469-479.
140. Grupp, S. A., Kalos, M., Barrett, D., Aplenc, R., Porter, D. L., Rhein-gold, S. R., Teachey, D. T., Chew, A., Hauck, B., Wright, J. F., Milone, M. C., Levine, B. L., June, C. H. (2013) Chimeric antigen receptor-modified T cells for acute lymphoid leukemia. N. Eng. J. Med. 368, 1509-1518.
141. Porter, D. L., Levine, B. L., Kalos, M., Bagg, A., June, C. H. (2011) Chi-meric antigen receptor-modified T cells in chronic lymphoid leukemia. N. Eng. J. Med. 365, 725-733.
142. Scholler, J., Brady, T. L., Binder-Scholl, G., Hwang, W. T., Plesa, G., Hege, K. M., Vogel, A. N., Kalos, M., Riley, J. L., Deeks, S. G., Mit-suyasu, R. T., Bernstein, W. B., Aronson, N. E., Levine, B. L., Bushman, F. D., June, C. H. (2012) Decade-long safety and function of retroviral-modified chimeric antigen receptor T cells. Science translational medicine. 4, 132ra53.
143. Kalos, M., Levine, B. L., Porter, D. L., Katz, S., Grupp, S. A., Bagg, A., June, C. H. (2011) T cells with chimeric antigen receptors have potent antitumor effects and can establish memory in patients with advanced leukemia. Science translational medicine. 3, 95ra73.
144. Morgan, R. A., Yang, J. C., Kitano, M., Dudley, M. E., Laurencot, C. M., Rosenberg, S. A. (2010) Case report of a serious adverse event following the administration of T cells transduced with a chimeric antigen receptor recognizing ERBB2. Molecular. therapy.:. the. journal. of. the. American. Society. of. Gene. Therapy. 18, 843-851.
145. Linette, G. P., Stadtmauer, E. A., Maus, M. V., Rapoport, A. P., Levine, B. L., Emery, L., Litzky, L., Bagg, A., Carreno, B. M., Cimino, P. J., Binder-Scholl, G. K., Smethurst, D. P., Gerry, A. B., Pumphrey, N. J., Bennett, A. D., Brewer, J. E., Dukes, J., Harper, J., Tayton-Martin, H. K., Jakobsen, B. K., Hassan, N. J., Kalos, M., June, C. H. (2013) Cardiovascular toxicity and titin cross-reactivity of affinity enhanced T cells in myeloma and melanoma. Blood.